Valuation: PREDILIFE

Market Cap 2.05M 2.25M 1.9M 1.71M 3.22M 210M 3.35M 22.91M 9.06M 113M 8.44M 8.26M 358M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 6.83M 7.49M 6.31M 5.7M 10.73M 700M 11.16M 76.27M 30.15M 378M 28.09M 27.51M 1.19B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day+0.38%
1 week-30.40%
Current month-38.59%
1 month-38.59%
3 months-53.81%
6 months-81.22%
Current year-82.66%
1 week 0.52
Extreme 0.52
0.65
1 month 0.52
Extreme 0.52
1.01
Current year 0.52
Extreme 0.52
4
1 year 0.52
Extreme 0.52
4
3 years 0.52
Extreme 0.52
24
5 years 0.52
Extreme 0.52
24
10 years 0.52
Extreme 0.52
24
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/23 Buy

Chief Executive Officer

1,200 0.0328%
3/23/22 Sell

Chief Executive Officer

3,000 0.0820%
3/9/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%-30.40%-83.16%-91.44% 2.25M
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.70%-3.63%+7.15%+89.57% 58.93B
+0.42%+0.45%+26.32%+87.29% 55.21B
-0.70%-3.26%+13.74%+114.17% 46.1B
-0.41%-5.13%+18.27%+25.29% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
+1.91%-6.89%+132.81%+655.64% 34.57B
+0.37%-0.20%+78.02%+58.69% 32.46B
+14.94%+17.26%-31.99%+462.33% 26.28B
Average +2.04%-5.14%+24.04%+151.71% 40B
Weighted average by Cap. +1.42%-2.69%+35.43%+149.43%

Financials

2024 2025
Net sales 493K 541K 456K 412K 775K 50.53M 806K 5.51M 2.18M 27.28M 2.03M 1.99M 86.13M 836K 916K 773K 697K 1.31M 85.64M 1.37M 9.33M 3.69M 46.22M 3.44M 3.37M 146M
Net income -4.26M -4.68M -3.94M -3.56M -6.7M -437M -6.97M -47.62M -18.83M -236M -17.54M -17.18M -745M -3.93M -4.31M -3.64M -3.28M -6.18M -403M -6.43M -43.94M -17.37M -218M -16.18M -15.85M -687M
Net Debt 3.54M 3.88M 3.27M 2.95M 5.56M 363M 5.78M 39.51M 15.62M 196M 14.56M 14.25M 618M 4.78M 5.24M 4.42M 3.99M 7.51M 490M 7.8M 53.35M 21.09M 264M 19.65M 19.24M 834M
Projected Income Statement - Annual - PREDILIFE
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
26-11-19 €0.5220 +0.38% 36
26-11-18 €0.5200 -10.65% 544
26-11-17 €0.5820 +0.34% 549
26-11-16 €0.5800 -7.94% 1,727
26-11-13 €0.6300 -16.00% 610

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - PREDILIFE
  1. Stock Market
  2. Stocks
  3. ALPRE Stock